BCDA
Biocardia·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
Bullish Abandoned Baby
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BCDA
Biocardia, Inc.
A clinical-stage biotechnology company developing innovative cardiovascular therapies, including cell-based treatments for heart failure
Biological Technology
01/12/1994
08/02/2019
NASDAQ Stock Exchange
17
12-31
Common stock
320 Soquel Way, Sunnyvale, California 94085
--
Biocardia, Inc., was incorporated in Delaware on January 12, 1994. The company is a clinical-stage regenerative medicine company developing novel therapies for cardiovascular diseases with significant unmet medical needs. The company's primary therapeutic candidate is the CardiAMP cell therapy system under development, which provides autologous bone marrow-derived cell therapy for the treatment of two clinical indications: heart failure that occurs after a heart attack and chronic myocardial ischemia.
Earnings Call
Q4/2024
Estimate EPS-0.87
Actual EPS--
Estimate Revenue22.50K
Actual Revenue--
BioCardia's Q4 2024: Regulatory Contradictions in CardiAMP's Japan Approval and Commercialization Strategy
Mar 31,2025 11:36
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.25
Actual EPS-0.24
Estimate Revenue--
Actual Revenue0
BioCardia's Q3 2025: Contradictions Emerge on Japan Regulatory Hurdles, CardiAMP Enrollment Strategies, and Trial Progress
Nov 13,2025 12:45
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS--
Actual EPS-0.59
Estimate Revenue--
Actual Revenue--
BioCardia's Q1 2025: Unpacking Key Contradictions in Japan Strategy and CardiAMP Trial Progress
May 20,2025 05:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS--
Actual EPS-0.4
Estimate Revenue--
Actual Revenue0
BioCardia's 2025 Q2 Earnings Call: Navigating Contradictions in CardiAMP's Regulatory Journey
Aug 11,2025 08:43
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BCDA has released its 2025 Q3 earnings. EPS was reported at -0.24, versus the expected -0.25, beating expectations. The chart below visualizes how BCDA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
